SOTAGLIFLOZIN



NAME OF DRUG : SOTAGLIFLOZIN

ALSO KNOWN AS : LX4211

LABORATORY : SANOFI

STATUS AND ADVANCEMENT

Type of drug : DUAL SGLT1 SGLT2 Inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated time to market : 123 months.

LABORATORY ABSTRACT ON THE DRUG

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is a first-in-class, oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. 

Lexicon entered into a collaboration and license agreement with Sanofi in November 2015 under which Lexicon granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license to develop, manufacture and commercialize sotagliflozin. Lexicon is responsible for all clinical development activities relating to type 1 diabetes and retains an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the U.S. Sanofi is responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide (excluding Japan) and is solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the U.S. (excluding Japan).

RECENT NEWS ON SOTAGLIFLOZIN

SOME PUBLICATIONS RELATED WITH SOTAGLIFLOZIN

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SOTAGLIFLOZIN


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE